Sandoz Completes Acquisition Of Just-Evotec Biologics

(RTTNews) - Sandoz (SDZ.SW) announced the completion of the acquisition of Just-Evotec Biologics EU SAS from Evotec SE. The deal includes the Toulouse development and manufacturing site and an indefinite licence to cutting-edge continuous-manufacturing technology for biosimilars. The company noted that the transaction is in line with existing capital-expenditure commitments and does not impact 2025 guidance.

The company said the milestone fully aligns with the Sandoz biosimilar strategy, expanding in-house drug substance development and manufacturing capabilities and leveraging continuous-manufacturing technology to boost efficiency and scalability.

For More Such Health News, visit rttnews.com.